drugset / Trial / NCT02172118
BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to assess the influence of severe renal impairment on the pharmacokinetics (PK), safety, and selected pharmacodynamic (PD) parameters of BI 1744 CL (30 μg administered by inhalation with the Respimat® Inhaler)
Timeline
- Start
- 2009-08
- Primary completion
- 2009-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1774 CL | Unknown | 30 ug | Inhaled |
Indications
No indication recorded.